The agency is currently reviewing the study findings ...

WASHINGTON — The Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to treat attention-deficit hyperactivity disorder to include warnings ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

News and commentary from the psychiatry world ...

A commonly used ADHD medication is being recalled nationwide after failing lab tests. The medication, lisdexamfetamine dimesylate capsules, is the generic form of Vyvanse, a stimulant that improves ...

Add Yahoo as a preferred source to see more of our stories on Google. Centanafadine showed significant improvements in ADHD symptoms compared with placebo. Credit: Inna Kot / Shutterstock.com. The US ...

A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

Kenvue, the American company that makes Tylenol, says the U.S. Food and Drug Administration should not make proposed changes to the product’s safety label to reflect research about a possible ...

October 7, 2010 — The US Food and Drug Administration (FDA) has approved clonidine hydrochloride, 0.1-mg and 0.2-mg, extended-release tablets (Kapvay; Shionogi Inc ...